ReviewThe EPMA journal2021
The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer.
Review in The EPMA journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The correlation between vaginal pathogens and high-risk human papilloma virus infection: a meta-analysis of case-control studies.Frontiers in oncology · 2024Pooled it
- Effectiveness of vaginal probioticsAging · 2024Trial
- Review
- Innate immune recognition and microenvironmental reprogramming in HPV-induced cervical cancer: from pattern recognition receptor activation to immune tolerance disruption.Frontiers in cellular and infection microbiology · 2026Review
- Integrating microbiome insights into cervical cancer.Frontiers in medicine · 2026Review
- Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review).Oncology letters · 2026Review
- Mapping the Vaginal Metabolic Profile in Dysbiosis, Persistent Human Papillomavirus Infection, and Cervical Intraepithelial Neoplasia: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles.NPJ biofilms and microbiomes · 2025Review
- Development of a predictive framework for ovarian reserve decline based on pelvic microbiota dysbiosis.The EPMA journal · 2025Article
- The role of innate immunity triggered by HPV infection in promoting cervical lesions.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Article
- Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women.The EPMA journal · 2025Review
- Unlocking the Interactions Between the Whole-Body Microbiome and HPV Infection: A Literature Review.Pathogens (Basel, Switzerland) · 2025Review
- Homogeneity Between Cervical and Vaginal Microbiomes and the Diagnostic Limitations of 16S Sequencing for STI Pathogens at Higher Ct Values.International journal of molecular sciences · 2025Article
- Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies.Heliyon · 2025Review
- Characterization of the vaginal microbiome of postmenopausal patients receiving chemoradiation for locally advanced cervical cancer.JCI insight · 2025Article
- HPV infection and the immune microenvironment in cervical cancer.Frontiers in immunology · 2025Review
- Vaginal Microecology Disturbance and Immune Dysregulation Are Associated with Human Papillomavirus Infection: Insights from a Two-year Study of Vaginal Microecology.International journal of general medicine · 2025Article
- The Role of the Vaginal Microbiome in Immune Modulation in Cervical Cancer: Composition, Molecular Mechanisms, and Therapeutic Potential.Clinical Medicine Insights. Oncology · 2025Review
- The vaginal microbiome in HPV persistence and cervical cancer progression.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HPVs representing the most common sexually transmitted disease are a group of carcinogenic viruses with different oncogenic potential. The immune system and the vaginal microbiome represent the modifiable and important risk factors in HPV-induced carcinogenesis. HPV infection significantly increases vaginal microbiome diversity, leading to gradual increases in the abundance of anaerobic bacteria and consequently the severity of cervical dysplasia. Delineation of the exact composition of the vaginal microbiome and immune environment before HPV acquisition, during persistent/progressive infections and after clearance, provides insights into the complex mechanisms of cervical carcinogenesis. It gives hints regarding the prediction of malignant potential. Relative high HPV prevalence in the general population is a challenge for modern and personalized diagnostics and therapeutic guidelines. Identifying the dominant microbial biomarkers of high-grade and low-grade dysplasia could help us to triage the patients with marked chances of lesion regression or progression. Any unnecessary surgical treatment of cervical dysplasia could negatively affect obstetrical outcomes and sexual life. Therefore, understanding the effect and role of microbiome-based therapies is a breaking point in the conservative management of HPV-associated precanceroses. The detailed evaluation of HPV capabilities to evade immune mechanisms from various biofluids (vaginal swabs, cervicovaginal lavage/secretions, or blood) could promote the identification of new immunological targets for novel individualized diagnostics and therapy. Qualitative and quantitative assessment of local immune and microbial environment and associated risk factors constitutes the critical background for preventive, predictive, and personalized medicine that is essential for improving state-of-the-art medical care in patients with cervical precanceroses and cervical cancer. The review article focuses on the influence and potential diagnostic and therapeutic applications of the local innate immune system and the microbial markers in HPV-related cancers in the context of 3P medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.